Eric Verdin and Brian Kennedy to speak at Rejuvenation Startup Summit 2022

Dr. Eric Verdin is the president and chief executive officer of the Buck Institute for Research on Aging. A native of Belgium, Dr. Verdin received his Doctorate of Medicine (MD) from the University of Liege and completed additional clinical and research training at Harvard Medical School. He has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), the Picower Institute for Medical Research and the Gladstone Institutes at UCSF. Dr. Verdin is also a professor of medicine at University of California, San Francisco and at the University of Southern California.

Eric has published more than 270 scientific papers and holds more than 15 patents. He is a highly cited scientist and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation. He is an elected member of several scientific organizations, including the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians. 

Dr. Verdin has extensive experience working with biotech companies. He is a founder of Acylin (purchased by Abbvie), Napa Therapeutics, BHB Therapeutics, Selah and Lyfspn.  He serves on the scientific advisory boards of multiple companies in the aging space.

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of ageing and as a visionary committed to translating research discoveries into new ways of detecting, delaying, preventing and treating human ageing and associated diseases. He is a Distinguished Professor in Biochemistry and Physiology at the Yong Loo Lin School of Medicine at National University Singapore (NUS) and serves as Director of (1) the Centre for Healthy Longevity at the National University Health System, (2) the Healthy Longevity Translational Research Programme and (3) the Asian Centre for Reproductive Longevity and Equality at NUS. Collectively, NUS ageing research seeks to demonstrate that longevity interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life.

From 2010 to 2016, Brian was the President and CEO of the Buck Institute for Research on Aging and he maintained a professorship there through 2020. Brian has an adjunct appointment at the Department of Biochemistry at the University of Washington, where he was a faculty member from 2001 to 2010. In addition, he is also actively involved with a number of Biotechnology companies and serves as a Co-Editor-In-Chief at Aging Cell. His Ph.D. was performed in the laboratory of Leonard Guarente at M.I.T., where he published the first paper linking Sirtuins to aging.

About the Rejuvenation Startup Summit 2022

The Rejuvenation Startup Summit (Berlin, Oct. 14-15, 2022) hosted by the Forever Healthy Foundation, is a vibrant networking event that aims to accelerate the development of the rejuvenation biotech industry.

Rejuvenation/Longevity biotech is a new, emerging field of medicine. It aims to prevent and reverse diseases of aging by addressing their common root cause, the aging process itself. Rejuvenation therapies aim to reverse or repair age-related cellular changes such as molecular waste, calcification, tissue stiffening, loss of stem cell function, genetic alterations, and impaired energy production.

The Rejuvenation Summit brings together startups, members of the longevity venture capital / investor ecosystem, and researchers interested in founding or joining a startup – all aiming to create therapies to vastly extend the healthy human lifespan.

Further information can be found at www.forever-healthy.org/summit/